@article {8195,
	title = {High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: Durable complete remissions, but a high rate of regimen-related toxicity},
	journal = {Bone Marrow Transplantation},
	volume = {15},
	year = {1995},
	note = {Cited By :52Export Date: 21 February 2017},
	month = {1995},
	pages = {549 - 555},
	abstract = {Forty-eight adult patients with recurrent or refractory intermediate grade or immunoblastic lymphoma received high-dose carmustine (BCNU), etoposide, Ara C and cyclophosphamide (BEAC), followed by autologous bone marrow transplantation (BMT). Median follow-up is 906 days (range 613-2067 days). The complete remission rate was 42\% and 22\% had a partial response. Actuarial failure-free survival is 30\% {\textpm} 6.6\%. Twenty one patients relapsed or progressed. Only one relapse occurred > 1 year after autologous BMT. Adverse prognostic factors for failure-free survival include high LDH at the time of autologous BMT, chemotherapy-refractory disease and multiple prior relapses. Patients with chemotherapy responsive first salvage (those achieving first CR only with salvage chemotherapy and those with first relapse, responding to salvage chemotherapy) had a failure-free survival of 52\% {\textpm} 10\% vs 12\% {\textpm} 6\% for those with more advanced disease. Of 13 patients who had no adverse factors, only two relapsed. Treatment-related mortality occurred in 23\%, including infection (n = 4), cardiac toxicity (n = 4), pulmonary toxicity (n = 2) and hemorrhage (n = 1). Pulmonary toxicity was more common among patients who had received prior radiation-therapy to the chest. BEAC chemotherapy with autologous BMT is an effective but relatively toxic regimen for patients with relapsed or refractory lymphomas. The combination of chemotherapy-responsive disease after failure of one chemotherapy regimen and normal LDH identifies patients with a favorable prognosis. Alternative cytotoxic regimens require evaluation, with the goal of reducing treatment related mortality. More effective cytoreductive therapy is required for patient with poor prognostic features.},
	keywords = {BEAC, Lymphoma},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029049140\&partnerID=40\&md5=9622fc63ca57d570b3e179421a07febf},
	author = {Van Besien, K. and Tabocoff, J. and Rodriguez, M. and Andersson, B. and Mehra, R. and Przepiorka, D. and Dimopoulos, M. and Giralt, S. and Suki, S. and Khouri, I. and Spitzer, G. and Jagannath, S. and Dicke, K. and LeMaistre, C.F. and Deisseroth, A. and Cabanillas, F. and Champlin, R.E.}
}
